Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 131
Biomarker Studies: Study Design and Statistical Considerations
From discovery to clinics: Design considerations in biomarker studies
Yingye Zheng
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Needle in a haystack: Biomarker discovery in high-dimensional data
Shilin Zhao
Vanderbilt University Medical Center, Nashville, TN, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Precision oncology: Integrating biomarkers in phase III clinical trial designs
Antje Hoering
Cancer Research and Biostatistics, Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Population risk stratification: Integrating biomarkers in cancer risk assessment
Ruth Pfeiffer
NCI-DCEG, Bethesda, MD, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
Discovery of BLU-667 for RET driven cancers
Jason Brubaker
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
Discovery and development of USP7 inhibitors
Tim Harrison
Almac Discovery, Belfast, Ireland
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
  •  
  • Permission not
    granted for presentation
  •  
  •  
Identification and optimization of chemical series that lead to discovery of erdafitinib: A potent pan-fibroblast growth factor receptor (FGFR) inhibitor
Patrick Angibaud
Janssen R & D, Val-de-Reuil, France
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680
Jenna Jeffrey
Arcus Biosciences, Inc., Hayward, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Clinical Trial Design: Part 1: The ABCs of Doing Cancer Clinical Trials
How to develop trial objectives: Translation of science from bench to bedside to bench
Patricia M LoRusso
Yale Cancer Center, New Haven, CT, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Clinical Trial Design: Part 1: The ABCs of Doing Cancer Clinical Trials
Modernizing eligibility criteria for oncology clinical trials
Tatiana Prowell
U.S. Food and Drug Administration and Johns Hopkins Kimmel Cancer Center, Silver Spring, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Clinical Trial Design: Part 1: The ABCs of Doing Cancer Clinical Trials
Biostatistical principals of clinical trial design
Mithat Gonen
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Clinical Trial Design: Part 1: The ABCs of Doing Cancer Clinical Trials
Designing meaningful and impactful clinical trials
Jyoti D Patel
Univ. of Chicago Medical Ctr., Chicago, IL, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The Evolution of the Art and Science of Go/No Go Decisions in Cancer Drug Development
The changing landscape of oncology drug development
David S Hong
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The Evolution of the Art and Science of Go/No Go Decisions in Cancer Drug Development
GO/NO GO decisions in cancer drug discovery: Has the decision making process evolved?
Nancy E. Kohl
Consultant, Wellesley, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The Evolution of the Art and Science of Go/No Go Decisions in Cancer Drug Development
Insights from a clinical development prediction algorithm: What we measure matters
David Feltquate
Bristol-Myers Squibb, New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The Evolution of the Art and Science of Go/No Go Decisions in Cancer Drug Development
  •  
  • Permission not
    granted for presentation
  •  
  •  
Pivotal decision making in oncology drug development: A perspective
Sandra J. Horning
Genentech, Inc., San Francisco, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Clinical Trial Design: Part 2: Novel Trial Designs
Is there a place for traditional phase 2 trials in cancer drug development?
Michael A. Carducci
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Clinical Trial Design: Part 2: Novel Trial Designs
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
The promises and challenges of master protocols: Basket and umbrella trials and beyond
Marc Theoret
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Clinical Trial Design: Part 2: Novel Trial Designs
Meaningful biostatistical outcomes of expansion cohort trials
Alexia Iasonos
Memorial Sloan Kettering Cancer Center, New Y ork, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Clinical Trial Design: Part 2: Novel Trial Designs
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
The multi-trial platform design: When and how?
Lorenzo Trippa
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Fluorescence Image-Guided Surgery for Improved Clinical Outcomes
Improving nerve tissue preservation using fluorescence guided surgery for improved clinical outcomes
Summer L Gibbs
Oregon Health & Science University, Portland, OR, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Fluorescence Image-Guided Surgery for Improved Clinical Outcomes
Microdose clinical trials update with fluorescent anti-EGFR Affibody ABY-029
Brian W Pogue
Dartmouth College, Hanover, NH, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Fluorescence Image-Guided Surgery for Improved Clinical Outcomes
  •  
  • Free
  • Coming soon
  • Some slides withheld
  •  
  •  
Optical and optoacoustic imaging: a hyperloop mechanism for drug development and optical tracer evaluation
Gooitzen M van Dam
University Medical Center Groningen, Groningen, Netherlands
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Fluorescence Image-Guided Surgery for Improved Clinical Outcomes
Optical surgical navigation using fluorescently labeled antibodies during head and neck cancer resection
Jason M. Warram
University of Alabama at Birmingham, Birmingham, AL, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Impact of a Brexit on Oncology Drug Development and Regulation
Introduction
Richard M. Marais
Cancer Research UK Manchester Inst., Manchester, United Kingdom
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 131